Targeted Quality Improvement Trial to Improve Post-Discharge VTE
Targeted Quality Improvement Trial to Improve Post-Discharge VTE Chemoprophylaxis After Abdominal and Pelvic Cancer Surgery
Venous thromboembolism (VTE) is the most common preventable cause of death after major abdominal and pelvic cancer surgery, and over one-third of events occur after discharge. National guidelines recommend extended post-discharge chemoprophylaxis, but hospital adherence varies widely. This observational study has two parts. Aim 1 uses interviews, focus groups, and surveys with patients, clinicians, and health system stakeholders to identify barriers and facilitators to implementing a post-discharge VTE chemoprophylaxis quality improvement project. Aim 2 uses retrospective hospital- and population-level data and coincidence analysis to identify hospital performance phenotypes and develop targeted implementation strategies. Findings will inform a separately registered stepped-wedge implementation trial (Aim 3).
調査の概要
詳細な説明
Aim 1: Semi-structured interviews, focus groups, and electronic surveys will be conducted with patients (n≈20) undergoing abdominal or pelvic cancer surgery, clinicians (n≈20), and health system stakeholders (n≈10). Surveys include study-specific VTE chemoprophylaxis and ordering surveys, the Organizational Readiness to Change Assessment (ORCA), and the Safety Attitudes Questionnaire (SAQ). Interviews are audio-recorded, transcribed, de-identified, and analyzed with hybrid inductive and deductive coding mapped to CFIR domains. Patient eligibility is screened through the medical record; screening data are not linked to survey or interview responses.
Aim 2: De-identified, retrospective hospital- and population-level data (demographics, procedure details, VTE prophylaxis orders, VTE outcomes), obtained through the University of Chicago Center for Research Informatics, will be analyzed using coincidence analysis (CNA) to identify causal pathways, define low- and high-performance hospital phenotypes, and develop targeted implementation strategies. Aim 2 data are kept separate from Aim 1 recruitment data.
This record covers Aims 1 and 2 only. The Aim 3 stepped-wedge trial is registered separately
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- University of Chicago
-
コンタクト:
- Jacob Ryno, MPH
- 電話番号:314-520-0355
- メール:jryno@uchicago.edu
-
主任研究者:
- Ryan P Merkow, MD, MS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients, clinicians, and health system stakeholders involved in abdominal and pelvic cancer surgery care, plus a retrospective hospital-level dataset.
説明
Inclusion Criteria:
- Patients: adults (18-85) undergoing abdominal and/or pelvic cancer surgery; English-speaking
- Clinicians: faculty and fellow physicians, advanced practice providers, physician assistants, medical assistants, dietitians, and social workers in participating surgical service clinics; English-speaking
- Stakeholders: Chief Medical Officer, Chief Information Officer, Chief Quality Officer, or related leadership
Aim 2: records of patients undergoing abdominal or pelvic cancer surgery between 1/1/2006 and 9/16/2025
Exclusion Criteria:
- Non-English-speaking individuals
- Patients not undergoing abdominal or pelvic cancer surgery
- Individuals under 18
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:OTHER
- 時間の展望:OTHER
コホートと介入
グループ/コホート |
|---|
|
Patients
Adults undergoing abdominal or pelvic cancer surgery at the University of Chicago Medical Center, interviewed or surveyed about post-discharge VTE chemoprophylaxis. |
|
Clinicians
Surgeons, advanced practice providers, nurses, and other clinical staff who care for abdominal and pelvic cancer surgery patients, interviewed or surveyed. |
|
Health System Stakeholders
Chief Medical, Information (or Medical Information), and Quality Officers and related leadership, interviewed. |
|
Retrospective Hospital/Patient Dataset (Aim 2)
De-identified, hospital- and population-level records of abdominal and pelvic cancer surgery patients, 2006-2025 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Barriers and facilitators to post-discharge VTE chemoprophylaxis implementation
時間枠:Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.
|
Themes identified from interviews and focus groups, coded and mapped to CFIR domains |
Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Organizational readiness to change (ORCA score)
時間枠:Year 1 and 2; Single survey at enrollment.
|
Survey scores, dichotomized as low or high |
Year 1 and 2; Single survey at enrollment.
|
|
Safety and quality culture (SAQ score)
時間枠:Year 1 and 2; Single survey at enrollment.
|
Survey scores, dichotomized as low or high. |
Year 1 and 2; Single survey at enrollment.
|
|
VTE chemoprophylaxis ordering patterns
時間枠:Year 1 and 2; Single survey at enrollment.
|
Survey responses on type of prophylaxis prescribed, reasoning, and risk factors. |
Year 1 and 2; Single survey at enrollment.
|
|
Hospital performance phenotypes
時間枠:Year 3; Following AIM 2 completion.
|
Number and characteristics of low- and high-performance phenotypes identified by coincidence analysis of Aim 1 and retrospective data. |
Year 3; Following AIM 2 completion.
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ryan Merkow, MS, MD、University of Chicago
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- IRB25-1360
- R01HL183429 (米国 NIH グラント/契約)
- IRB25-1360 (その他の識別子:UChicago IRB)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualitative recordings and transcripts will not be shared. De-identified data will be retained in secure University of Chicago storage, and any external sharing would require IRB review
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。